SDHB mutation carriers are reported to develop metastatic PGL more frequently and patients with metastatic disease associated with SDHB variants are reported to have a poor 5-year survival rate compared to patients with metastatic disease associated with other causative genes [11]. Here, SDHB is linked to metastatic neoplasm.